Cysal GmbH

Cysal GmbH uses an in­ter­na­tion­ally patented, biotech­no­log­i­cal process to pro­duce argininea­s­par­tate and ly­sine-as­par­tate dipep­tides on an in­dus­trial scale. The biotech­nol­ogy com­pany uses these dipep­tides, a com­bi­na­tion of two amino acids, as the base ma­te­r­ial for the man­u­fac­ture of fin­ished prod­ucts de­vel­oped in-house such as en­ergy ton­ics, skin creams, fish feed ad­di­tives, and in­fu­sions. The com­pany was es­tab­lished in 2012 as a spin-off from the In­sti­tute for Mol­e­c­u­lar Mi­cro­bi­ol­ogy and Biotech­nol­ogy at the West­phalian Wil­helms-Uni­ver­sity in Münster. The Man­ag­ing Di­rec­tor, Dr. Ahmed Sal­lam, founded Cysal to­gether with Dr. Mar­tin Kre­hen­brink of the Uni­ver­sity of Ox­ford.